PATHEON INC. (PTI - TORONTO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PATHEON INC. (PTI - TORONTO)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Nykol who wrote (2)	3/22/1997 3:31:00 PM
From: Francoise Kartha	of 147

News release Nykol, I found the following while scanning ISDN. PATHEON SECURES CONTRACTS TO MANUFACTURE TOPICAL STEROIDS 1997-03-20 TORONTO, ONTARIO ------------------------------------------------------------------------ Patheon Inc. (TSE: PTI) announced today that it has entered into contracts with Phoenix-based Medicis Pharmaceutical Corporation (NASDAQ:MDRX) to manufacture topical steroid brands LIDEX(R) nd SYNALAR(R). Medicis recently announced that it has completed the acquisition of these brands from Syntex (U.S.A.) Inc. and its affiliated companies. Medicis is currently conducting an aggressive sampling and promotional campaign for LIDEX(R) and SYNALAR(R) targeting dermatologists across the United States and Canada. According to our projections based on historical demand, these contracts will provide initial annual revenues in the $3 million to $4 million range. Manufacturing of these two prescription compounds will be carried out at the Company's recently acquired facility on Syntex Court in Mississauga, and is scheduled to begin in the second quarter of this fiscal year. These contracts are consistent with Patheon's strategy to provide more profitable, higher value-added services to the pharmaceutical industry. Medicis, headquartered in Phoenix, Arizona, is the leading independent dermatology company in the United States, offering prescription and non-prescription productions exclusively to treat dermatologic conditions. Medicis currently markets DYNACIN(R), TRIAZ(R), BENZASHAVE(R) and THERAMYCIN(TM)Z prescription products for the treatment of acne and acne-related conditions as well as ESOTERICA(R) fade creams and THERAPLEX(R) moisturizers and shampoos. Patheon Inc. is one of North America's leading independent providers of manufacturing and drug development services in the rapidly growing pharmaceutical outsourcing sector. With the recent acquisition of the Hoffmann-La Roche manufacturing facility near Toronto's International Airport in Mississauga. Ontario, the Company and its 48%-owned Global Pharm affiliate operate five cGMP facilities in Canada employing over 400 people. Patheon serves nine of the world's ten largest pharmaceutical companies. Contact: Mr. Robert C. Tedford Chief Executive Officer Tel: 905-812-6760 Fax: 905-812-6705

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next